Update on the treatment of multisystem inflammatory syndrome in children associated with COVID-19
| Autor: | Fangyuan Long, Shiheng Zhu, Zeguang Wang, Shungeng Zhang, Jinlong He, Xinbin Ge, Jun Ning |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Future Virology. 18:63-74 |
| ISSN: | 1746-0808 1746-0794 |
| DOI: | 10.2217/fvl-2022-0048 |
| Popis: | In late 2019, SARS-CoV-2 was detected in China and spread worldwide. In rare cases, children who were infected with COVID-19 may develop multisystem inflammatory syndrome (MIS-C), which could have higher mortality than COVID-19 itself. Therefore, diagnosis and management are critical for treatment. Specifically, most of the initial treatment options of MIS-C choose intravenous immunoglobulin (IVIG) and steroids as the first-line treatment for patients. Moreover, antagonists of some cytokines are used as potential future therapeutics. Of note, therapeutic plasmapheresis can be used as a treatment for refractory severe MIS-C. We believe that each patient, especially those with comorbid conditions, should have individualized treatment based on both multidisciplinary consensus approach and expert opinion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|